Progenics Pharma (PGNX) Reports Q4 Loss of $0.04/Share

Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.04), versus ($0.10) reported last year. Revenue for the quarter came in at $3.9 million, versus $4.65 million reported last year.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance